根据美国证券交易委员会（SEC）最新文件披露，生物技术公司Century Therapeutics, Inc.已通过投资银行TD Cowen成功售出价值1,840万美元的普通股。此次交易规模较此前市场传闻的“可能融资1.5亿美元”存在显著差异，文件明确澄清了实际融资额度。
该文件显示，此次股票发售采用非公开配售方式，由TD Cowen作为独家代理机构完成。融资款项将主要用于推进公司肿瘤治疗管线的临床研发，包括针对血液恶性肿瘤和实体瘤的异体细胞疗法项目。
市场观察人士指出，此次融资规模虽低于早期传闻，但仍反映出投资人对Century Therapeutics技术平台的认可。公司专有的iPSC（诱导多能干细胞）技术平台能够规模化生产通用型细胞疗法，在肿瘤免疫治疗领域具有独特优势。
值得注意的是，此次SEC文件特别对融资金额进行了更正说明，强调实际完成金额为1,840万美元，而非部分媒体早前报道的1.5亿美元潜在融资计划。这一澄清有助于投资者更准确地评估公司当前资金状况和发展规划。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.